X4 Pharmaceuticals, Inc. (XFOR) Stock Forecast
XFOR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $11.60 average of analyst targets
- Upside to target
- +347.9% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.19
- 52-week range
- $2.45 – $4.67
XFOR analyst ratings
5 analystsNumber of analysts at each rating.
XFOR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
XFOR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.22 | −$0.16 | −$0.69 | +73.0% | 5 |
| Current fiscal year (2026) | −$0.67 | −$0.79 | −$0.59 | −$1.87 | +64.3% | 5 |
| Next fiscal year (2027) | −$0.77 | −$1.00 | −$0.65 | −$0.67 | −14.9% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
XFOR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.3M | $1.5M | $2.9M | +30.3% | 5 |
| Current fiscal year (2026) | $16.0M | $14.5M | $17.3M | −54.5% | 5 |
| Next fiscal year (2027) | $11.6M | $6.5M | $17.3M | −27.7% | 5 |
XFOR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
XFOR revenue: reported and forecast
XFOR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.19 | −$0.19 | −$0.19 | −$0.19 | −5.8% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.76 | −$0.73 | −$0.67 | −$0.67 | −$0.67 | −11.5% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.91 | −$0.82 | −$0.76 | −$0.76 | −$0.77 | −16.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
XFOR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; XFOR beat in 8 of 12.
What analysts expect from XFOR
5 analysts cover X4 Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.60, 347.9% above the latest close of $2.59. Analysts expect earnings of −$0.67 per share for 2026, +64.3% from a year earlier. For 2027 the average estimate is −$0.77 per share on revenue of $11.6 million. X4 Pharmaceuticals beat the EPS estimate in 8 of the last 12 quarters.
Related: XFOR income statement, XFOR key metrics, XFOR chart. See the XFOR stock overview for the latest quote and news.
XFOR forecast FAQ
What is X4 Pharmaceuticals's price target?
The average analyst price target for X4 Pharmaceuticals is $11.60, 347.9% above the latest close of $2.59.
Is X4 Pharmaceuticals a buy, hold or sell?
Of 5 analysts covering X4 Pharmaceuticals, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is X4 Pharmaceuticals's EPS forecast?
Analysts forecast −$0.67 per share for 2026 (range −$0.79 to −$0.59); for 2027 the estimate is −$0.77.
What is X4 Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $16.0 million, growth of −54.5%; for 2027 it is $11.6 million.
When does X4 Pharmaceuticals report earnings?
X4 Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.19.
Does X4 Pharmaceuticals usually beat earnings estimates?
X4 Pharmaceuticals reported EPS at or above the analyst estimate in 8 of the last 12 quarters.